These include tumour promoting molecules such as VEGF to provide anti-angiogenic therapy (e.g., bevacizumab), IL-6, and MIF (macrophage migration-inhibitory factor), immune checkpoint inhibitors (e.g., PD-1 and CTLA-4), as well as TAAs, e.g., HER2 [286]. The gene discussed is CTLA4; the disease is neoplasm.